Xeris Biopharma Holdings, Inc. XERS Gvoke — Product revenue, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s gvoke — product revenue, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s gvoke — product revenue, net?
- Xeris Biopharma Holdings, Inc. (XERS) reported gvoke — product revenue, net of $20.8M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s gvoke — product revenue, net changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s gvoke — product revenue, net decreased by 0.2% year-over-year, from $20.85M to $20.8M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s gvoke — product revenue, net?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s gvoke — product revenue, net has grown at a 24.7% compound annual growth rate (CAGR), from $38.92M to $94.11M.
- What does gvoke — product revenue, net mean?
- This metric represents the total net sales generated from the specific pharmaceutical product line after accounting for returns, rebates, and other sales deductions. It serves as a primary indicator of market adoption, commercial success, and the underlying demand for the therapy within its therapeutic category. Tracking this revenue stream helps investors assess the product's growth trajectory and its contribution to the company's overall top-line performance.